Rafael Mesquita1, Daisy J A Janssen, Emiel F M Wouters, Jos M G A Schols, Fabio Pitta, Martijn A Spruit. 1. Program Development Center, Center of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands; Centro de Pesquisa em Ciências da Saúde, Centro de Ciências Biológicas e da Saúde, Universidade Norte do Paraná (UNOPAR), Londrina, Paraná, Brazil; Laboratório de Pesquisa em Fisioterapia Pulmonar, Departamento de Fisioterapia, Universidade Estadual de Londrina (UEL), Londrina, Paraná, Brazil. Electronic address: rafaelmesquita14@ymail.com.
Abstract
OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF). DESIGN: Cross-sectional. SETTING: Patients' home environment. PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72). INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: Time to complete the TUG test. Three trials were performed on the same day and by the same assessors. The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated. RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00. However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01). The third trial added little or no information to the first 2 trials. For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups. CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials. Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.
OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF). DESIGN: Cross-sectional. SETTING:Patients' home environment. PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72). INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: Time to complete the TUG test. Three trials were performed on the same day and by the same assessors. The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated. RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00. However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01). The third trial added little or no information to the first 2 trials. For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups. CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials. Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.
Authors: Rafael Mesquita; Sarah Wilke; Dionne E Smid; Daisy Ja Janssen; Frits Me Franssen; Vanessa S Probst; Emiel Fm Wouters; Jean Wm Muris; Fabio Pitta; Martijn A Spruit Journal: Chron Respir Dis Date: 2016-07-08 Impact factor: 2.444
Authors: Sarah Wilke; Dionne E Smid; Martijn A Spruit; Daisy J A Janssen; Jean W M Muris; Thys van der Molen; Marjan van den Akker; Paul W Jones; Emiel F M Wouters; Frits M E Franssen Journal: Chronic Obstr Pulm Dis Date: 2014-09-25
Authors: Jan Cameron; Peter G Rendell; Chantal F Ski; Christina E Kure; Skye N McLennan; Nathan S Rose; David L Prior; David R Thompson Journal: Trials Date: 2015-04-29 Impact factor: 2.279
Authors: Dionne E Smid; Sarah Wilke; Paul W Jones; Jean W M Muris; Emiel F M Wouters; Frits M E Franssen; Martijn A Spruit Journal: BMJ Open Date: 2015-07-21 Impact factor: 2.692
Authors: Ali Mufraih Albarrati; Nichola S Gale; Stephanie Enright; Margaret M Munnery; John R Cockcroft; Dennis J Shale Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-08-02
Authors: Matthew J Clarkson; Steve F Fraser; Paul N Bennett; Lawrence P McMahon; Catherine Brumby; Stuart A Warmington Journal: BMC Nephrol Date: 2017-09-11 Impact factor: 2.388